Influenza virus vaccine (Optaflu, Flucelvax) - Seqirus

Drug Profile

Influenza virus vaccine (Optaflu, Flucelvax) - Seqirus

Alternative Names: Flucelvax; Flucelvax Pediatric; Flucelvax Quadrivalent; Influenza vaccine (Flucelvax); Influenza vaccine (prepared in cell culture) - Seqirus; Optaflu; TIVc

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Seqirus
  • Class Influenza virus vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 22 Jun 2017 Withdrawn for Influenza virus infections (Prevention, In adults) in Ireland, Netherlands, Poland, Portugal, United Kingdom, Czech Republic, Austria (IM)
  • 22 Jun 2017 Marketing Authorisation for influenza virus vaccine (Optaflu®) expires in European Union, Norway, Iceland and Liechtenstein
  • 23 May 2016 Registered for Influenza virus infections (In adults, In adolescents, In children, Prevention) in USA (IM) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top